
Clinical Pearls for Management of Pediatric Atopic Dermatitis With Topicals
Panelists discuss how dermatologists should expand their therapeutic scope beyond traditional steroids and calcineurin inhibitors to embrace newer nonsteroidal options, while emphasizing that treating pediatric atopic dermatitis requires the same principles as adult care and encouraging broader provider participation, including pediatricians, to address access challenges.
Health care providers should embrace the expanding range of nonsteroidal topical treatments available for children with atopic dermatitis, moving beyond traditional reliance on corticosteroids and calcineurin inhibitors alone. Many dermatologists remain hesitant to prescribe newer medications due to unfamiliarity with mechanisms of action or concern about cost and insurance coverage, yet these treatments often prove more accessible and affordable than expected. Patient copay assistance programs frequently make brand-name treatments cost less than traditional generic options; the improved safety profiles allow for confident long-term use without monitoring requirements.
Pediatric patients with atopic dermatitis deserve access to the same therapeutic advances available to adults. The principles of treatment remain remarkably consistent across age groups despite common concerns about treating children differently. General dermatologists and pediatricians can successfully manage pediatric atopic dermatitis using similar approaches to adult treatment, with the main limitations being age-specific FDA indications rather than fundamental differences in disease management. The shortage of pediatric dermatology specialists makes it essential for broader health care provider groups to feel confident treating these patients with modern therapeutic options.
Families benefit from simplified, practical treatment approaches that combine effective acute management with sustainable long-term maintenance strategies tailored to their specific needs and capabilities. The most successful treatment plans involve education-focused visits that address fears about medication safety, demonstrate proper application techniques, and establish realistic expectations about chronic disease management. Success requires matching treatment complexity to family capacity for adherence, with willingness to escalate to systemic options when topical regimens become impractical, ensuring that patients receive effective treatment regardless of the modality required.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















